Table 1.
Response to treatment with bosutinib given as second or third line in patients with chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia.
| Response | Second-line CP-CML treatment |
Third-line CP-CML treatment |
Advanced phases |
|||||
|---|---|---|---|---|---|---|---|---|
| IM resistant (n = 200) | IM intolerant (n = 88) | IM+DAS resistant (n = 37) | IM+DAS intolerant (n = 50) | IM+NIL resistant (n = 27) | AP CML (n = 63) | BP CML (n = 48) | Ph+ ALL (n = 23) | |
| CHR | 86% | 85% | 62% | 80% | 76% | 61% | 32% | 25% |
| CCyR | 41% | 41% | 19% | 43% | 27% | 33% | 29% | 100% |
| CMR | 49% | 61% | 0% | 19% | 11% | 4% | 12% | 23% |
CP-CML, chronic phase chronic myeloid leukemia; IM, imatinib; DAS, dasatinib; NIL, nilotinib; AP, advanced phase; BP, blast phase; Ph+ ALL, Philadelphia chromosome positive acute lymphoblastic leukemia; CHR, complete hematological remission; CCyR, complete cytogenetic remission; CMR, complete molecular remission.